help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lufkin, E. G.
Right arrow Articles by Knox, F. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lufkin, E. G.
Right arrow Articles by Knox, F. G.

Journal of Clinical Endocrinology & Metabolism, Vol 50, 648-653, Copyright © 1980 by Endocrine Society

ARTICLES

Phosphorus excretion in tumoral calcinosis: response to parathyroid hormone and acetazolamide

EG Lufkin, DM Wilson, LH Smith, NJ Bill, HF DeLuca, TP Dousa and FG Knox

The cause of hyperphosphatemia in patients with tumoral calcinosis never been explained. We studied two related patients who had tumoral calcinosis and hyperphosphatemia and two normal controls to determine their renal tubular response to parathyroid hormone (PTH) and acetazolamide (ACZ). During baseline periods, the patients had abnormally low fractional excretion of phosphorus (FEP) despite their hyperphosphatemia. Values for patients were 0.114 and 0.128; for controls, values were 0.193 and 0.165. PTH caused an increase in FEP and urinary cAMP in both patients and controls. ACZ also increased FEP in both groups, and the effects of PTH and ACZ were additive, suggesting that patients with tumoral calcinosis have normal sensitivities to PTH and normal responses to ACZ. Levels of vitamin D metabolites in the patients were normal. We conclude that patients with tumoral calcinosis have a reduced ability to excrete phosphorus. This defect does not seem to be due to impaired PTH secretion, an abnormal phosphaturic response to this hormone, or a disturbance of vitamin D metabolism.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
H. J. Garringer, C. Fisher, T. E. Larsson, S. I. Davis, D. L. Koller, M. J. Cullen, M. S. Draman, N. Conlon, A. Jain, N. S. Fedarko, et al.
The Role of Mutant UDP-N-Acetyl-{alpha}-D-Galactosamine-Polypeptide N-Acetylgalactosaminyltransferase 3 in Regulating Serum Intact Fibroblast Growth Factor 23 and Matrix Extracellular Phosphoglycoprotein in Heritable Tumoral Calcinosis
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4037 - 4042.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
K. M. Olsen and F. S. Chew
Tumoral calcinosis: pearls, polemics, and alternative possibilities.
RadioGraphics, May 1, 2006; 26(3): 871 - 885.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. Benet-Pages, P. Orlik, T. M. Strom, and B. Lorenz-Depiereux
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
Hum. Mol. Genet., February 1, 2005; 14(3): 385 - 390.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society